{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:20:12Z","timestamp":1790734812314,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82300395"],"award-info":[{"award-number":["82300395"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2023M743198"],"award-info":[{"award-number":["2023M743198"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12715-y","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T12:53:30Z","timestamp":1753534410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Liraglutide attenuates autoimmune myocarditis by inhibiting NLRP3 and NF-\u03bab pathways"],"prefix":"10.1038","volume":"15","author":[{"given":"Lijuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishuai","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanzhou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"12715_CR1","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1056\/NEJMra2114478","volume":"387","author":"C Basso","year":"2022","unstructured":"Basso, C. & Myocarditis. N Engl. J. Med. 387, 1488\u20131500, doi: https:\/\/doi.org\/10.1056\/NEJMra2114478 (2022).","journal-title":"N Engl. J. Med."},{"key":"12715_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-3-319-57613-8_10","volume":"1003","author":"W Bracamonte-Baran","year":"2017","unstructured":"Bracamonte-Baran, W. & \u010cih\u00e1kov\u00e1, D. Cardiac autoimmunity: myocarditis. Adv. Exp. Med. Biol. 1003, 187\u2013221. https:\/\/doi.org\/10.1007\/978-3-319-57613-8_10 (2017).","journal-title":"Adv. Exp. Med. Biol."},{"key":"12715_CR3","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/cvr\/cvad029","volume":"119","author":"Y Lu","year":"2023","unstructured":"Lu, Y. et al. Inhibition of phosphoglycerate kinase 1 attenuates autoimmune myocarditis by reprogramming CD4\u2009+\u2009T cell metabolism. Cardiovasc. Res. 119, 1377\u20131389. https:\/\/doi.org\/10.1093\/cvr\/cvad029 (2023).","journal-title":"Cardiovasc. Res."},{"key":"12715_CR4","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck, M. A., Quast, D. R., Wefers, J. & Meier, J. J. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol. Metab. 46, 101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102 (2021).","journal-title":"Mol. Metab."},{"key":"12715_CR5","doi-asserted-by":"publisher","unstructured":"Alharbi, S. H. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther. Adv. Endocrinol. Metab. 15 https:\/\/doi.org\/10.1177\/20420188231222367 (2024).","DOI":"10.1177\/20420188231222367"},{"key":"12715_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jot.2022.02.001","volume":"32","author":"C Meurot","year":"2022","unstructured":"Meurot, C. et al. Targeting the GLP-1\/GLP-1R axis to treat osteoarthritis: A new opportunity? J. Orthop. Translat. 32, 121\u2013129. https:\/\/doi.org\/10.1016\/j.jot.2022.02.001 (2022).","journal-title":"J. Orthop. Translat"},{"key":"12715_CR7","doi-asserted-by":"publisher","unstructured":"Balogh, D. B., Wagner, L. J. & Fekete, A. An overview of the cardioprotective effects of novel antidiabetic classes: focus on inflammation, oxidative stress, and fibrosis. Int. J. Mol. Sci. 24 https:\/\/doi.org\/10.3390\/ijms24097789 (2023).","DOI":"10.3390\/ijms24097789"},{"key":"12715_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","volume":"40","author":"J Helmst\u00e4dter","year":"2020","unstructured":"Helmst\u00e4dter, J. et al. Endothelial GLP-1 (Glucagon-Like Peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension. Arterioscler. Thromb. Vasc Biol. 40, 145\u2013158. https:\/\/doi.org\/10.1161\/atv.0000615456.97862.30 (2020).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"12715_CR9","doi-asserted-by":"publisher","unstructured":"Li, R. et al. Liraglutide ameliorates TAC-induced cardiac hypertrophy and heart failure by upregulating expression level of ANP expression. Heliyon 10 e32229. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e32229   (2024).","DOI":"10.1016\/j.heliyon.2024.e32229"},{"key":"12715_CR10","doi-asserted-by":"publisher","unstructured":"Fang, B. et al. Liraglutide alleviates myocardial ischemia\u2013reperfusion injury in diabetic mice. Mol. Cell. Endocrinol. 572 https:\/\/doi.org\/10.1016\/j.mce.2023.111954 (2023).","DOI":"10.1016\/j.mce.2023.111954"},{"key":"12715_CR11","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1161\/CIRCULATIONAHA.110.952820","volume":"122","author":"A Cruz-Adalia","year":"2010","unstructured":"Cruz-Adalia, A. et al. CD69 limits the severity of cardiomyopathy after autoimmune myocarditis. Circulation 122, 1396\u20131404. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.952820 (2010).","journal-title":"Circulation"},{"key":"12715_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/cns.13791","volume":"28","author":"S Song","year":"2022","unstructured":"Song, S. et al. Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway. CNS Neurosci. Ther. 28, 422\u2013434. https:\/\/doi.org\/10.1111\/cns.13791 (2022).","journal-title":"CNS Neurosci. Ther."},{"key":"12715_CR13","doi-asserted-by":"publisher","first-page":"2180951","DOI":"10.1080\/21505594.2023.2180951","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y., Zhou, X., Chen, S., Sun, X. & Zhou, C. Immune mechanisms of group B coxsackievirus induced viral myocarditis. Virulence 14, 2180951. https:\/\/doi.org\/10.1080\/21505594.2023.2180951 (2023).","journal-title":"Virulence"},{"key":"12715_CR14","doi-asserted-by":"publisher","unstructured":"Kanehisa, M. & Goto, S. 14 KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28 27\u201330.  https:\/\/doi.org\/10.1093\/nar\/28.1.27   (2000).","DOI":"10.1093\/nar\/28.1.27"},{"key":"12715_CR15","doi-asserted-by":"publisher","unstructured":"Lu, Y. et al. Acacetin alleviates autoimmune myocarditis by regulating CD4\u2009+\u2009T cell mitochondrial respiration. Chin. Med. 19 https:\/\/doi.org\/10.1186\/s13020-024-00943-9 (2024).","DOI":"10.1186\/s13020-024-00943-9"},{"key":"12715_CR16","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.22038\/ijbms.2021.56771.12677","volume":"24","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z., Wang, X., Yang, L., Yang, L. & Ma, H. Liraglutide ameliorates myocardial damage in experimental diabetic rats by inhibiting pyroptosis via Sirt1\/AMPK signaling. Iran. J. Basic. Med. Sci. 24, 1358\u20131365. https:\/\/doi.org\/10.22038\/ijbms.2021.56771.12677 (2021).","journal-title":"Iran. J. Basic. Med. Sci."},{"key":"12715_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jacbts.2022.08.002","volume":"8","author":"M Punjabi","year":"2023","unstructured":"Punjabi, M. et al. Liraglutide lowers endothelial vascular cell adhesion Molecule-1 in murine atherosclerosis independent of glucose levels. JACC Basic. Transl Sci. 8, 189\u2013200 (2023).","journal-title":"JACC Basic. Transl Sci."},{"key":"12715_CR18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jacc.2024.04.064","volume":"84","author":"A Chowdhary","year":"2024","unstructured":"Chowdhary, A. et al. Liraglutide improves myocardial perfusion and energetics and exercise tolerance in patients with type 2 diabetes. J. Am. Coll. Cardiol. 84, 540\u2013557. https:\/\/doi.org\/10.1016\/j.jacc.2024.04.064 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"12715_CR19","doi-asserted-by":"publisher","unstructured":"Wu, Y. R. et al. Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1\/2 pathway. Cardiovasc. Diabetol. 18 https:\/\/doi.org\/10.1186\/s12933-019-0954-6 (2019).","DOI":"10.1186\/s12933-019-0954-6"},{"key":"12715_CR20","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s00125-009-1643-x","volume":"53","author":"I Hadjiyanni","year":"2010","unstructured":"Hadjiyanni, I., Siminovitch, K. A., Danska, J. S. & Drucker, D. J. Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 53, 730\u2013740. https:\/\/doi.org\/10.1007\/s00125-009-1643-x (2010).","journal-title":"Diabetologia"},{"key":"12715_CR21","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","volume":"54","author":"AE Hogan","year":"2011","unstructured":"Hogan, A. E. et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia 54, 2745\u20132754. https:\/\/doi.org\/10.1007\/s00125-011-2232-3 (2011).","journal-title":"Diabetologia"},{"key":"12715_CR22","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1016\/j.apsb.2022.06.003","volume":"12","author":"J Pang","year":"2022","unstructured":"Pang, J., Feng, J. N., Ling, W. & Jin, T. The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs-Therapeutic potential exploration in lung injury. Acta Pharm. Sin B. 12, 4040\u20134055. https:\/\/doi.org\/10.1016\/j.apsb.2022.06.003 (2022).","journal-title":"Acta Pharm. Sin B"},{"key":"12715_CR23","doi-asserted-by":"publisher","unstructured":"Liu, X. et al. Mitochondrial calpain-1 activates NLRP3 inflammasome by cleaving ATP5A1 and inducing mitochondrial ROS in CVB3-induced myocarditis. Basic. Res. Cardiol. 117 https:\/\/doi.org\/10.1007\/s00395-022-00948-1 (2022).","DOI":"10.1007\/s00395-022-00948-1"},{"key":"12715_CR24","doi-asserted-by":"publisher","first-page":"727838","DOI":"10.3389\/fphar.2021.727838","volume":"12","author":"W Liang","year":"2021","unstructured":"Liang, W. et al. Sacubitril\/Valsartan alleviates experimental autoimmune myocarditis by inhibiting Th17 cell differentiation independently of the NLRP3 inflammasome pathway. Front. Pharmacol. 12, 727838. https:\/\/doi.org\/10.3389\/fphar.2021.727838 (2021).","journal-title":"Front. Pharmacol."},{"key":"12715_CR25","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.ceca.2022.102590","volume":"104","author":"S Yang","year":"2022","unstructured":"Yang, S. et al. Blockage of transient receptor potential vanilloid 4 prevents postoperative atrial fibrillation by inhibiting NLRP3-inflammasome in sterile pericarditis mice. Cell. Calcium. 104, 102590. https:\/\/doi.org\/10.1016\/j.ceca.2022.102590 (2022).","journal-title":"Cell. Calcium"},{"key":"12715_CR26","doi-asserted-by":"publisher","unstructured":"Lu, Y. et al. Targeting the NLRP3 inflammasome abrogates cardiotoxicity of immune checkpoint blockers. J. Immunother. Cancer. 13 (e010127). https:\/\/doi.org\/10.1136\/jitc-2024-010127 (2025).","DOI":"10.1136\/jitc-2024-010127"},{"key":"12715_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.abb.2019.07.008","volume":"671","author":"X Luo","year":"2019","unstructured":"Luo, X. et al. Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation. Arch. Biochem. Biophys. 671, 203\u2013209. https:\/\/doi.org\/10.1016\/j.abb.2019.07.008 (2019).","journal-title":"Arch. Biochem. Biophys."},{"key":"12715_CR28","doi-asserted-by":"publisher","first-page":"107534","DOI":"10.1016\/j.intimp.2021.107534","volume":"95","author":"Z Li","year":"2021","unstructured":"Li, Z. et al. The expression of STAT3 inhibited the NF-\u039aB signalling pathway and reduced inflammatory responses in mice with viral myocarditis. Int. Immunopharmacol. 95, 107534. https:\/\/doi.org\/10.1016\/j.intimp.2021.107534 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"12715_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10557-013-6463-z","volume":"27","author":"Y Dai","year":"2013","unstructured":"Dai, Y., Mehta, J. L. & Chen, M. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc. Drugs Ther. 27, 371\u2013380. https:\/\/doi.org\/10.1007\/s10557-013-6463-z (2013).","journal-title":"Cardiovasc. Drugs Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12715-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12715-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12715-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T01:37:50Z","timestamp":1757295470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12715-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12715"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12715-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27274"}}